Michael Barbella, Managing Editor11.15.23
Perosphere Technologies Inc. has received two federal grants totaling more than $2 million to further develop and commercialize its point-of-care (PoC) coagulometer, the Perosphere Technologies POC Coagulometer.
Bestowed upon the company was a Direct Phase II Small Business Innovation Research (SBIR) grant from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH); and a subaward through an Atlanta Center for Microsystems Engineered Point-of-Care Technologies (ACME POCT) Center Grant, funded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB/NIH).
“We are very honored to receive these grants from NIH and ACME POCT, as they will present a unique opportunity to further expand our groundbreaking point-of-care coagulation diagnostics technology,” said Dr. Stefan Zappe, principal investigator and chief technology officer at Perosphere Technologies. “Perosphere Technologies aims to revolutionize coagulation testing by providing healthcare professionals with accurate and timely results.”
The device’s portability and versatility make it well-suited for emergency room and emergency vehicle use, as well as for routine care in inpatient and outpatient settings including hospitals, clinics, surgical suites, doctor’s offices, and pharmacies. Perosphere's PoC Coagulometer informs diagnosis, treatment, and prevention through precision data, made immediately accessible to all. It is the only point-of-care diagnostic tool that effectively and swiftly tests clotting times across drug classes, including Direct Oral Anticoagulants (DOACs), according to the company. The PoC Coagulometer is approved in the European Union but not (yet) in the United States.
“The potential applications of the Perosphere Technologies PoC Coagulometer will greatly expand thanks to these grant awards, accelerating our understanding of disease mechanisms and therapeutic approaches,” Perosphere Technologies CEO Dr. Sasha Bakhru. “We are proud of the work and research that have gone into creating this device. By providing physicians with the tools to make faster, better-informed treatment decisions, our technology has strong potential to significantly enhance patient care.”
Perosphere Technologies is a private medical technologies company based in Danbury, Conn.
Bestowed upon the company was a Direct Phase II Small Business Innovation Research (SBIR) grant from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH); and a subaward through an Atlanta Center for Microsystems Engineered Point-of-Care Technologies (ACME POCT) Center Grant, funded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB/NIH).
“We are very honored to receive these grants from NIH and ACME POCT, as they will present a unique opportunity to further expand our groundbreaking point-of-care coagulation diagnostics technology,” said Dr. Stefan Zappe, principal investigator and chief technology officer at Perosphere Technologies. “Perosphere Technologies aims to revolutionize coagulation testing by providing healthcare professionals with accurate and timely results.”
The device’s portability and versatility make it well-suited for emergency room and emergency vehicle use, as well as for routine care in inpatient and outpatient settings including hospitals, clinics, surgical suites, doctor’s offices, and pharmacies. Perosphere's PoC Coagulometer informs diagnosis, treatment, and prevention through precision data, made immediately accessible to all. It is the only point-of-care diagnostic tool that effectively and swiftly tests clotting times across drug classes, including Direct Oral Anticoagulants (DOACs), according to the company. The PoC Coagulometer is approved in the European Union but not (yet) in the United States.
“The potential applications of the Perosphere Technologies PoC Coagulometer will greatly expand thanks to these grant awards, accelerating our understanding of disease mechanisms and therapeutic approaches,” Perosphere Technologies CEO Dr. Sasha Bakhru. “We are proud of the work and research that have gone into creating this device. By providing physicians with the tools to make faster, better-informed treatment decisions, our technology has strong potential to significantly enhance patient care.”
Perosphere Technologies is a private medical technologies company based in Danbury, Conn.